These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 15380020)
1. Lack of alpha-synuclein does not alter apoptosis of neonatal catecholaminergic neurons. Stefanis L; Wang Q; Oo T; Lang-Rollin I; Burke RE; Dauer WT Eur J Neurosci; 2004 Oct; 20(7):1969-72. PubMed ID: 15380020 [TBL] [Abstract][Full Text] [Related]
2. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. Li W; Lee MK J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070 [TBL] [Abstract][Full Text] [Related]
3. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
5. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505 [TBL] [Abstract][Full Text] [Related]
6. Synucleins and their relationship to Parkinson's disease. von Bohlen Und Halbach O Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152 [TBL] [Abstract][Full Text] [Related]
7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
9. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685 [TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Golovko MY; Faergeman NJ; Cole NB; Castagnet PI; Nussbaum RL; Murphy EJ Biochemistry; 2005 Jun; 44(23):8251-9. PubMed ID: 15938614 [TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336 [TBL] [Abstract][Full Text] [Related]
12. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569 [TBL] [Abstract][Full Text] [Related]
13. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595 [TBL] [Abstract][Full Text] [Related]
14. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease. Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676 [TBL] [Abstract][Full Text] [Related]
15. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. Rockenstein E; Schwach G; Ingolic E; Adame A; Crews L; Mante M; Pfragner R; Schreiner E; Windisch M; Masliah E J Neurosci Res; 2005 Apr; 80(2):247-59. PubMed ID: 15765523 [TBL] [Abstract][Full Text] [Related]